Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...

Gilead Sciences, Inc. (NASDAQ:GILD) plans to present over 20 research abstracts—spanning both Gilead and its cell therapy unit Kite—at two major medical conferences: the 2025 ASCO Annual Meeting (May ...

Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy ...

Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. The California-based pharma ...

Gilead Sciences is ready to shop. Here's why Kite, Tesaro, and Intercept might be good selections to add to the biotech's cart. Gilead CEO John Milligan mentioned in the last earnings call that ...